Compare BioNano Genomics Inc (BNGO) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Keysight Technologies Inc — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Keysight Technologies Inc trades at $353.45 (market cap $58.74B). The key difference: Keysight Technologies Inc is far larger — about 4300.1× BioNano Genomics Inc's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | KEYS | |
|---|---|---|
Market Cap | $13.66M | $58.74B |
Sector | Health | Technology |
52-Week High | $4.92 | $373.34 |
52-Week Low | $1.06 | $158.51 |
Enterprise Value | $16.26M | $59.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Keysight Technologies (KEYS) trades at $335.41, down 1.63% on the day, with a bullish technical outlook and strong analyst support. The stock exhibits robust fundamentals, including a 17.31% net income margin and consistent earnings beats, with Q1 2026 EPS of $2.87 surpassing the $2.32 estimate. Recent developments include new product launches and strategic collaborations, such as the certification of electromagnetic design software for Intel's latest processes (Business Wire, 2026-07-27).
The outlook for KEYS is positive, driven by earnings growth and innovation in test and measurement solutions. Key opportunities include expansion in 5G and cybersecurity markets, though risks involve high valuation multiples and competitive pressures. The consensus price target of $396.56 implies significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
